Company Performance - Medpace's stock closed at $582.48, reflecting a decrease of -1.79% from the previous day, underperforming compared to the S&P 500's daily loss of 0.43% [1] - Over the last month, Medpace's shares have increased by 5.59%, outperforming the Medical sector's loss of 2.36% and the S&P 500's gain of 0.89% [1] Upcoming Earnings - Medpace is set to disclose its earnings on February 9, 2026, with analysts expecting earnings of $4.18 per share, indicating a year-over-year growth of 13.9% [2] - The consensus estimate for revenue is projected at $681.17 million, representing a growth of 26.94% compared to the same quarter last year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $14.8 per share and revenue of $2.5 billion, reflecting changes of +17.18% and 0% respectively from the prior year [3] - Recent changes to analyst estimates indicate a positive outlook for Medpace, as upward revisions are often seen as a sign of optimism regarding business trends [3] Valuation Metrics - Medpace has a Forward P/E ratio of 35.67, which is a premium compared to the industry average Forward P/E of 15.73 [6] - The company has a PEG ratio of 1.99, compared to the Medical Services industry's average PEG ratio of 1.77 [6] Industry Context - The Medical Services industry, which includes Medpace, ranks 178 in the Zacks Industry Rank, placing it in the bottom 28% of over 250 industries [7] - The Zacks Industry Rank evaluates the performance potential of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Medpace (MEDP) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10] Group 1: Earnings Growth - Medpace has a historical EPS growth rate of 32%, with projected EPS growth of 17.1% for the current year, surpassing the industry average of 15.7% [4] - The importance of double-digit earnings growth is emphasized as a key indicator of strong company prospects and potential stock price gains [3] Group 2: Cash Flow Growth - Medpace's year-over-year cash flow growth stands at 40.3%, significantly higher than the industry average of -1.2%, indicating robust financial health [5] - The company's annualized cash flow growth rate over the past 3-5 years is 26%, compared to the industry average of 7.7%, showcasing its superior performance [6] Group 3: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Medpace, with the Zacks Consensus Estimate for the current year increasing by 5.3% over the past month [8] - The correlation between earnings estimate revisions and near-term stock price movements supports the stock's potential for growth [7]

Core Viewpoint - Medpace (MEDP) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of changing earnings estimates in determining stock price movements, making it a valuable tool for investors [2][3]. - A strong correlation exists between earnings estimate revisions and near-term stock movements, with institutional investors playing a role in this relationship by adjusting their valuations based on earnings estimates [3]. Medpace's Earnings Outlook - Medpace is projected to earn $14.79 per share for the fiscal year ending December 2025, with no year-over-year change expected [7]. - Over the past three months, the Zacks Consensus Estimate for Medpace has increased by 5.7%, reflecting analysts' positive revisions [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6]. - Medpace's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Viewpoint - Medpace (MEDP) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - Changes in earnings estimates are strongly correlated with near-term stock price movements, influenced by institutional investors who adjust their valuations based on these estimates [4]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade suggest an improvement in Medpace's underlying business, which could lead to increased stock prices as investors respond positively [5][10]. - The Zacks Consensus Estimate for Medpace has increased by 8.3% over the past three months, with expected earnings of $13.99 per share for the fiscal year ending December 2025, indicating stability year-over-year [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, positioning Medpace among the best candidates for potential market-beating returns [9][10].

Core Viewpoint - The market anticipates Medpace (MEDP) will report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended June 2025 [1][3]. Earnings Expectations - The consensus EPS estimate for Medpace is $3.00 per share, reflecting a year-over-year increase of +9.1% [3]. - Expected revenues for the quarter are $541.19 million, which is a 2.5% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.81%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Medpace is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.91%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with positive readings being more reliable [9][10]. - Medpace currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [12]. Historical Performance - In the last reported quarter, Medpace exceeded the expected earnings of $3.06 per share by delivering $3.67, resulting in a surprise of +19.93% [13]. - The company has successfully beaten consensus EPS estimates in the last four quarters [14]. Conclusion - While Medpace does not appear to be a strong candidate for an earnings beat based on current estimates, investors should consider other factors before making investment decisions [17].

Core Viewpoint - Medpace (MEDP) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The earnings report is scheduled for release on April 21, 2025, and could lead to a stock price increase if the results exceed expectations, while a miss could result in a decline [2]. - The Zacks Consensus Estimate predicts quarterly earnings of $3.06 per share, reflecting a year-over-year decrease of 4.4%, with revenues expected to reach $530.12 million, a 3.7% increase from the previous year [3]. Estimate Revisions - Over the past 30 days, the consensus EPS estimate has been revised down by 1.5%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Medpace is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.42%, suggesting a bearish outlook from analysts [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, with a positive Earnings ESP indicating a higher likelihood of an earnings beat [6][8]. - Medpace's current Zacks Rank is 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [11]. Historical Performance - In the last reported quarter, Medpace was expected to post earnings of $2.97 per share but exceeded expectations with earnings of $3.67, resulting in a surprise of +23.57% [12]. - The company has successfully beaten consensus EPS estimates in the last four quarters [13]. Conclusion - While Medpace does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].